Drug Trial Radar · NCT02291289
A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)
Last checked: Nov 19, 2026Latest source record: May 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,044
Actual
Start
Apr 17, 2015
Primary completion
May 31, 2019
Study completion Mar 24, 2021
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Nov 14, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized, multi-center, active-controlled, open-label, parallel-group study will investigate the efficacy and safety of biomarker-driven maintenance treatment for first-line mCRC. Participants with mCRC are eligible for entry and cannot have received any prior chemotherapy in the metastatic setting. The entire study duration is anticipated to be approximately 7.5 years.
Conditions
- Colorectal Cancer
Interventions
CetuximabDrug
500 mg/m\^2 via IV infusion on Day 1 of every 2-week cycle
FOLFOX induction regimenDrug
Administered per the Investigator's discretion in accordance with locally approved prescribing information.
Fluoropyrimidine (5-FU/LV or capecitabine)Drug
Per Investigator's discretion: 5-FU 1600-2400 mg/m\^2 administered via 46-hour IV infusion on Day 1 of every 2-week cycle and LV 400 mg/m\^2 administered via a 2-hour infusion on Day 1 every 2 weeks or 1000 mg/m\^2 twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The chosen fluoropyrimidine should be administered in accordance with local prescribing information.
AtezolizumabDrug
800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle, or a fixed dose of 840 mg
VemurafenibDrug
960 mg vermurafenib BID by mouth
BevacizumabDrug
5 mg/kg bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle per local prescribing information
TrastuzumabDrug
Initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses by IV infusion on Day 1 of every 3-week treatment cycle
PertuzumabDrug
Initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses by IV infusion on Day 1 of each 3-week treatment cycle
CobimetinibDrug
60 mg orally once daily for 3 weeks followed by a 1-week treatment break
5-FU/LVDrug
1600-2400 mg/m\^2 5-FU via 46-hour IV infusion in combination with 400 mg/m\^2 LV via 2-hour infusion on Day 1 of every 2-week cycle until disease progression per the Investigator's assessment using modified Response Evaluation Criteria in Solid Tumors or death from any cause, whichever occurs first. The fluoropyrimidine should be administered in accordance with local prescribing information.
CapecitabineDrug
1000 mg/m\^2 twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The fluoropyrimidine should be administered in accordance with local prescribing information.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: From randomization until disease progression or death from any cause, up to 5 years
Locations
154 sites in 23 countries. Site status is shown where the registry gives one.
Hospital de Gastroenterologia Dr. Bonorino Udaondo ; Servicio de Oncología
Buenos Aires, Argentina
Centro Oncologico Riojano Integral (CORI)
La Rioja, Argentina
Clínica Viedma
Viedma Rio Negro, Argentina
Institut Jules Bordet X
Brussels, Belgium
Hospital Erasme
Brussels, Belgium
UZ Leuven Gasthuisberg
Leuven, Belgium
CHC MontLégia
Liège, Belgium
AZ Delta (Campus Rumbeke)
Roeselare, Belgium
University Clinical Center of the Republic of Srpska
Banja Luka, Bosnia and Herzegovina
Hospital da Cidade de Passo Fundo; Centro de Pesquisa em Oncologia
Passo Fundo, Rio Grande do Sul, Brazil
Hospital das Clinicas - UFRGS
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Nossa Senhora da Conceicao
Porto Alegre, Rio Grande do Sul, Brazil
Hospital de Cancer de Barretos
Barretos, São Paulo, Brazil
Hospital Amaral Carvalho
Jaú, São Paulo, Brazil
Faculdade de Medicina de Sao Jose do Rio Preto - FAMERP*X*
São José do Rio Preto, São Paulo, Brazil
Instituto de Ensino e Pesquisa Sao Lucas - IEP
São Paulo, São Paulo, Brazil
Herlev Hospital; Afdeling for Kræftbehandling
Herlev, Denmark
Regionshospitalet Gødstrup; Kræftafdelingen
Herning, Denmark
Rigshospitalet; Onkologisk Klinik
København Ø, Denmark
Odense Universitetshospital, Onkologisk Afdeling R
Odense C, Denmark
Sygehus Syd Roskilde; Onkologisk/haematologisk ambulatorium
Roskilde, Denmark
National Cancer Institute
Cairo, Egypt
Ain Shams University Hospital; Oncology
Cairo, Egypt
Clinique Sainte Catherine
Avignon, France
HOPITAL JEAN MINJOZ; Oncologie
Besançon, France
Hopital Augustin Morvan; Federation De Cancerologie
Brest, France
Chu Estaing; Chir Generale Digestive A Et B
Clermont-Ferrand, France
Hôpital Franco-Britannique- Fondation Cognacq-Jay; Cancerologie
Levallois-Perret, France
Hopital Claude Huriez; Medecine Interne Oncologie
Lille, France
Ch De Montbeliard;Chir Generale Digestive
Montbéliard, France
Hopital Caremeau; Gastro Enterologie
Nîmes, France
Hopital Saint Antoine; Oncologie Medicale
Paris, France
Hopital Haut Leveque
Pessac, France
Chu La Miletrie; Gastro Enterologie Endoscopies
Poitiers, France
ICANS
Strasbourg, France
Hopital Rangueil; Gastro Enterologie Et Nutrition
Toulouse, France
Institut Gustave Roussy; Departement Oncologie Medicale
Villejuif, France
Hämatologie Onkologie im Zentrum MVZ GmbH
Augsburg, Germany
Onkologische Schwerpunktpraxis Kurfürstendamm
Berlin, Germany
DRK Kliniken Berlin Köpenick Darmzentrum
Berlin, Germany
Showing 40 of 154 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.